Last reviewed · How we verify
CF102
At a glance
| Generic name | CF102 |
|---|---|
| Also known as | Cl-IB-MECA, IB-MECA, 2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide |
| Sponsor | Can-Fite BioPharma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis (PHASE3)
- Namodenoson Treatment of Advanced Pancreatic Cancer (PHASE2)
- Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) (PHASE2)
- Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) (PHASE2)
- A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma (PHASE1, PHASE2)
- A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease (PHASE2)
- A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1 (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |